CA 19-9 (Pancreatic Cancer Marker)
CA 19-9 is a tumor marker blood test used to monitor pancreatic cancer and other digestive tract cancers. It helps track treatment response and cancer progression.
Order this test
LevelPanel has no business or affiliate relationship with Quest or LabCorp. These links are provided as a public service.
Lab testing services linked from this site are not available to residents of Alaska, Arizona, or Hawaii, unless otherwise noted on the lab's own website.
This publication is not intended to solicit the purchase of laboratory testing from any individual consumer.
What this test measures
CA 19-9 (cancer antigen 19-9) is a carbohydrate antigen found on the surface of certain cells and released into the bloodstream. It is most commonly associated with pancreatic cancer, where elevated levels are found in the majority of patients with advanced disease. However, other cancers of the digestive tract (including colorectal, gastric, and bile duct cancers) can also produce elevated readings.
Like other tumor markers, CA 19-9 is not specific to a single disease. Elevated levels can occur in a variety of non-cancerous conditions, including bile duct obstruction, cholestasis, jaundice, pancreatitis, cirrhosis, and gallbladder disease. Additionally, approximately 5% to 10% of the population lacks the enzyme needed to produce CA 19-9, meaning these individuals will never show elevated levels regardless of disease status. For these reasons, CA 19-9 is not used as a standalone screening or diagnostic tool. Its primary value is in monitoring disease progression and treatment response in patients with known pancreatic or other digestive-tract cancers.
Who should consider this test
You might consider this test if you are experiencing any of the following:
- Individuals who have been diagnosed with pancreatic cancer and need to monitor their treatment response and disease progression, as CA 19-9 levels can help healthcare providers assess whether treatment is working effectively.
- Patients who have completed pancreatic cancer treatment and require ongoing surveillance to detect potential cancer recurrence, as rising CA 19-9 levels may indicate the cancer has returned.
- Those with suspected pancreatic cancer who are undergoing additional diagnostic testing, where CA 19-9 levels may provide supporting information when combined with imaging studies and other diagnostic procedures.
- People with other digestive tract cancers such as bile duct cancer (cholangiocarcinoma), colorectal cancer, or gallbladder cancer, where elevated CA 19-9 levels may assist in monitoring disease status.
- Individuals at high risk for pancreatic cancer due to family history or genetic predisposition who may benefit from periodic monitoring as part of a comprehensive surveillance plan recommended by their healthcare provider.
What to expect
Preparation
No fasting is required for the CA 19-9 test. Patients should inform their healthcare provider about any medications or supplements they are taking, as some may potentially affect results.
Sample Type
A simple blood draw from a vein in the arm using a small needle. The procedure typically takes just a few minutes and may involve a brief pinch when the needle is inserted.
Collection
At the lab location, a healthcare professional will clean the area, insert a small needle to collect the blood sample, and apply a bandage. The sample is then labeled and sent to the laboratory for analysis.
Turnaround
Results are typically available within 1-2 business days after the sample reaches the laboratory, with no doctor visit required to receive your confidential test results.
Understanding your results
Normal CA 19-9 levels fall below 37 U/mL (units per milliliter). Levels above this threshold may indicate cancer, but can also result from benign biliary or pancreatic conditions, so an elevated result requires further clinical investigation. In patients being monitored for known pancreatic cancer, trends in CA 19-9 over time are more informative than single readings: declining values during treatment suggest response, while rising values may signal progression. Healthcare providers interpret CA 19-9 alongside imaging, pathology, symptoms, and other diagnostic information, and never rely on this marker alone to make clinical decisions.
| Population | Reference Range | Notes |
|---|---|---|
| Adults | 0-37 U/mL | Normal reference range for healthy individuals; levels above this range may warrant further evaluation |
Reference ranges may vary by laboratory and individual factors. Results should be interpreted by a healthcare provider in the context of your overall health.
What does a “Low” result mean?
CA 19-9 levels in the normal range (0-37 U/mL) typically suggest the absence of significant tumor activity, though this must be interpreted carefully. Approximately 5% of the population is unable to produce the CA 19-9 antigen, and about 6% of the white population and 22% of the black population in the United States are Lewis antigen-negative and do not generate the specific sialyl antigen, which will result in falsely negative CA 19-9 levels even in the presence of pancreatic cancer. Low or normal CA 19-9 levels do not definitively rule out pancreatic cancer or other malignancies, particularly in early-stage disease. Healthcare providers may recommend additional testing or monitoring even with normal CA 19-9 levels if other clinical factors suggest the possibility of cancer.
What does a “High” result mean?
CA 19-9 levels above 37 U/mL may indicate cancer, though it's also possible to have a benign condition that causes CA 19-9 levels to rise. Sometimes a person will fall in the normal range for CA 19-9 even if they have a type of cancer that usually produces it. A high CA 19-9 is usually related to pancreatic cancer, but other cancers like colorectal, lung and gallbladder cancers can also cause raised levels. Elevated levels may also be caused by non-cancerous conditions including pancreatitis, bile duct disease, liver disease, gallstones, or cystic fibrosis. Healthcare providers typically order additional tests and imaging studies to determine the underlying cause of elevated levels. When CA 19-9 levels are greater than 1000 U/mL, the positive predictive value and specificity approach 100% and are correlated with unresectable tumors. However, even significantly elevated levels require comprehensive evaluation by healthcare professionals to determine the specific cause and appropriate next steps.
Privacy & confidentiality
All CA 19-9 test results are strictly confidential and protected under HIPAA regulations. Results are not sent to your personal doctor unless you specifically request it, will not be added to your medical records, and will not appear on insurance EOB statements since no doctor visit is required for testing.
Frequently asked questions
Related tests
CEA (Carcinoembryonic Antigen)
Another tumor marker often used alongside CA 19-9 for monitoring digestive tract cancers
View TestCA 125
Complementary tumor marker that can improve discrimination between different types of cancer
View TestAFP (Alpha-fetoprotein)
Additional tumor marker used in comprehensive cancer screening panels
View TestLiver Panel
Helps evaluate liver function and rule out liver-related causes of elevated CA 19-9
View TestLast reviewed: April 2026
CPT Code: 86301
This test may not be available in: NY, NJ, RI
This page is for informational purposes only and does not constitute medical advice. Always consult with a healthcare provider regarding any health concerns. LevelPanel does not diagnose, treat, or prescribe.
Order this test
Choose your preferred lab
LevelPanel has no business or affiliate relationship with Quest or LabCorp. These links are provided as a public service.
Lab testing services linked from this site are not available to residents of Alaska, Arizona, or Hawaii, unless otherwise noted on the lab's own website.
This publication is not intended to solicit the purchase of laboratory testing from any individual consumer.
Not sure if this is the right test? Contact our care team for guidance.
This page is intentionally kept stable and machine-readable so that researchers, clinicians, and AI systems can rely on it as a reference. See our Citation Policy.